Tetraphase Pharmaceuticals (TTPH) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Tetraphase Pharmaceuticals (NASDAQ:TTPH) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.02), Morningstar.com reports. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%. The business had revenue of $1.15 million for the quarter, compared to analysts’ expectations of $2.09 million.

TTPH traded down $0.08 on Friday, reaching $2.17. The stock had a trading volume of 808,354 shares, compared to its average volume of 1,007,372. Tetraphase Pharmaceuticals has a 12-month low of $2.01 and a 12-month high of $6.97. The stock has a market capitalization of $117.35 million, a price-to-earnings ratio of -0.83 and a beta of 2.67.

Several research analysts recently issued reports on TTPH shares. HC Wainwright reissued a “buy” rating on shares of Tetraphase Pharmaceuticals in a report on Monday, July 16th. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 30th. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a report on Thursday, August 2nd. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Friday, August 3rd. Finally, B. Riley lifted their price objective on shares of Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, August 28th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $6.16.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its holdings in Tetraphase Pharmaceuticals by 3.7% in the second quarter. BlackRock Inc. now owns 4,172,314 shares of the biopharmaceutical company’s stock valued at $14,895,000 after buying an additional 149,866 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Tetraphase Pharmaceuticals by 9.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 275,630 shares of the biopharmaceutical company’s stock valued at $984,000 after buying an additional 23,337 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in Tetraphase Pharmaceuticals in the second quarter valued at $104,000. Canada Pension Plan Investment Board purchased a new position in Tetraphase Pharmaceuticals in the second quarter valued at $179,000. Finally, Dimensional Fund Advisors LP increased its holdings in Tetraphase Pharmaceuticals by 20.1% in the second quarter. Dimensional Fund Advisors LP now owns 2,200,413 shares of the biopharmaceutical company’s stock valued at $7,855,000 after buying an additional 367,672 shares in the last quarter. 41.02% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/11/09/tetraphase-pharmaceuticals-ttph-posts-quarterly-earnings-results-misses-estimates-by-0-02-eps.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Recommended Story: Fundamental Analysis – How It Helps Investors

Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply